Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Change in fasting triglyceride levels
研究概览
简要总结
Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease and type II diabetes development, and is independently associated with all-cause mortality, making it an important disease target. The primary treatment for MetSyn is exercise and weight loss, along with medically necessary treatment. Exercise, along with dietary changes such as increased fiber and polyphenol intake can positively impact many of the metabolic abnormalities seen with MetSyn. For example, polyphenols have been shown to decrease lipid concentration and improved glucose clearance as well as decreased oxidative stress and inflammation. Powdered tart cherry capsules, which contain the skin of the fruit, provides polysaccharides (fiber) that would likely act as a substrate for gut bacteria degradation, providing energy substrates and barrier integrity to the colonocytes and increasing the bioavailability of the polyphenols to other cells in the body. However there have been no long-term investigations into the use of powdered tart cherry supplements in MetSyn, therefore we aim to determine if 60 days tart cherry supplementation modify criteria for MetSyn in currently diagnosed individuals including body mass, waist circumference, blood pressure, blood lipid levels and blood glucose control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have been diagnosed with metabolic syndrome by a physician or meet the diagnostic criteria: Waist circumference greater than 40 inches (men) or greater than 35 inches (women), High blood pressure (greater than 130/80) or taking medication for high blood pressure, High triglycerides (greater than 150 mg/dL) or low HDL (less than 40 for men, less than 50 for women), High fasting blood glucose (100-126 mg/dL) or diagnosed as pre-diabetic
- •Age 25-60
排除标准
- •currently taking medication for glucose or lipid control, such as metformin and/or statin
- •currently using anti-inflammatory medications & have not used corticosteroids in the last two months
- •diagnosed with or currently being treated for an inflammatory condition
- •major organ system impairment (heart failure, renal failure, severe impairment of respiratory function)
- •currently a smoker or quit less than 12 months ago
结局指标
主要结局
Change in fasting triglyceride levels
时间窗: baseline, 30 days post supplementation, 60 days post supplmentation
Change in baseline systolic and diastolic blood pressure
时间窗: baseline, 60 days post supplmentation
Change in waist circumference
时间窗: baseline, 60 days post supplmentation
Change in erythrocyte sedimentation rate
时间窗: baseline, 30 days post supplementation, 60 days post supplmentation
Change in fasting high-density lipoprotein (HDL) cholesterol
时间窗: baseline, 30 days post supplementation, 60 days post supplmentation
Change in body fat distribution
时间窗: baseline, 60 days post supplmentation
Change in fasting blood glucose level
时间窗: baseline, 30 days post supplementation, 60 days post supplmentation
次要结局
未报告次要终点
研究者
Angela Hillman
Assistant Professor of Exercise Physiology
Ohio University
